AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
October 16, 2024
FDA Approves New Once-Weekly Therapy for Hemophilia A or B
October 14, 2024
REGULATORY UPDATE: FDA Updates Biological Product Deviation Reporting Codes
October 02, 2024